Abstract | BACKGROUND: OBSERVATIONS: Tissue sample analysis showed highly elevated expression of IL-23 on both transcriptional and protein level in a recalcitrant PG lesion. On the basis on these data, a treatment targeting the p40 subunit of the heterodimeric IL-23 with the monoclonal antibody ustekinumab was started. Therapy with ustekinumab resulted in a significant decrease of IL-23 expression in PG and healing after 14 weeks of treatment. No relapse occurred in a 6-month follow-up period. CONCLUSIONS: Our data provide evidence of an IL-23-dominated inflammatory infiltrate in PG. This might specify a new concept for PG pathophysiology and suggests a possibility for using ustekinumab as a therapeutic agent in this disease.
|
Authors | Emmanuella Guenova, Anna Teske, Birgit Fehrenbacher, Sebastian Hoerber, Annette Adamczyk, Martin Schaller, Wolfram Hoetzenecker, Tilo Biedermann |
Journal | Archives of dermatology
(Arch Dermatol)
Vol. 147
Issue 10
Pg. 1203-5
(Oct 2011)
ISSN: 1538-3652 [Electronic] United States |
PMID | 21680759
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunosuppressive Agents
- Interleukin-23
- Ustekinumab
- Tacrolimus
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Drug Therapy, Combination
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Interleukin-23
(antagonists & inhibitors, biosynthesis)
- Molecular Targeted Therapy
- Pyoderma Gangrenosum
(diagnosis, drug therapy, pathology)
- Tacrolimus
(therapeutic use)
- Treatment Outcome
- Ustekinumab
|